Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis

Recommendations for restricting the exposure to radiation of members of the public coming into contact with thyrotoxic patients treated with I are currently based on the activity retained by the patient, and not on the doses likely to be received by such individuals. In order to examine whether thes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nuclear medicine communications 1993-03, Vol.14 (3), p.160-168
Hauptverfasser: OʼDOHERTY, M J, KETTLE, A G, EUSTANCE, C N.P, MOUNTFORD, P J, COAKLEY, A J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 168
container_issue 3
container_start_page 160
container_title Nuclear medicine communications
container_volume 14
creator OʼDOHERTY, M J
KETTLE, A G
EUSTANCE, C N.P
MOUNTFORD, P J
COAKLEY, A J
description Recommendations for restricting the exposure to radiation of members of the public coming into contact with thyrotoxic patients treated with I are currently based on the activity retained by the patient, and not on the doses likely to be received by such individuals. In order to examine whether these current recommendations restrict these doses to less than the current annual limit of 5 mSv, and to identify the implications of a reduction in this limit to 1 mSv, measurements were made of the dose rates at distances of 0.1, 0.5 and 1.0 m from 60 patients just before they left the nuclear medicine department. These measurements were repeated 1, 3, 6, 8 and 10 days after administration for 30 patients, and the radioactivity in samples of saliva taken on each of these days and secreted in sweat over the first 24 h were also measured. Doses were estimated for administered activities of approximately 200–600 MBq, assuming appropriate values for the times and distances spent near other individuals while travelling, at work, at home and near to young children considered in three age groups (
doi_str_mv 10.1097/00006231-199303000-00003
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00006231_199303000_00003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8455905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2313-c2e3615504a953e652560604daa0eab2b8e0ab2aa09afd4bcb06766d6f884ef63</originalsourceid><addsrcrecordid>eNp1UctOwzAQtBColMInIPnANWBnbSc5oopHpUpIFZwjJ1lTQxpHdkrp3-PS0hs-eHd2ZlbWmBDK2S1nRXbH4lEp8IQXBTCIKNmN4ISMucggkSrNT8mYcQEJKFDn5CKEj6jIQWUjMsqFlAWTY7JY6MbqwbqONi4g9XrAQI13K6qbdTvQPpLYDYF6rNF-2e6dcuAzOizR635LjfOx33o3uG9bu2DDJTkzug14dagT8vb48Dp9TuYvT7Pp_Typ48Mh3giKS8mELiSgkqlUTDHRaM1QV2mVI4slokKbRlR1xVSmVKNMngs0CiYk3--tvQvBoyl7b1fab0vOyl1K5V9K5TGl3xFE6_Xe2q-rFTZH4yGWyN8ceB1q3Rqvu9qGo0woJdJMRJnYyzauHdCHz3a9QV8uUbfDsvzvj-AHmAd_Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>OʼDOHERTY, M J ; KETTLE, A G ; EUSTANCE, C N.P ; MOUNTFORD, P J ; COAKLEY, A J</creator><creatorcontrib>OʼDOHERTY, M J ; KETTLE, A G ; EUSTANCE, C N.P ; MOUNTFORD, P J ; COAKLEY, A J</creatorcontrib><description>Recommendations for restricting the exposure to radiation of members of the public coming into contact with thyrotoxic patients treated with I are currently based on the activity retained by the patient, and not on the doses likely to be received by such individuals. In order to examine whether these current recommendations restrict these doses to less than the current annual limit of 5 mSv, and to identify the implications of a reduction in this limit to 1 mSv, measurements were made of the dose rates at distances of 0.1, 0.5 and 1.0 m from 60 patients just before they left the nuclear medicine department. These measurements were repeated 1, 3, 6, 8 and 10 days after administration for 30 patients, and the radioactivity in samples of saliva taken on each of these days and secreted in sweat over the first 24 h were also measured. Doses were estimated for administered activities of approximately 200–600 MBq, assuming appropriate values for the times and distances spent near other individuals while travelling, at work, at home and near to young children considered in three age groups (&lt;2, 2–5 and 5–11 years). Periods of restriction were derived which would reduce these doses to 5 or 1 mSv. For a dose limit of 5 mSv, there is no need to restrict private travel, public transport journeys can last up to 7 h, a patient can return to work immediately, but sleeping with a partner will have to be restricted even for the minimum activity of 200 MBq. For a dose limit of 1 mSv, public transport journeys should not exceed 1 h for an administered activity of 600 MBq or 3.5 h for 200 MBq, and return to work should be delayed if the administered activity exceeds 300 MBq. The periods to restrict close contact with young children in order to limit their dose to 1 mSv were very similar to the current recommendations based on retained activity.</description><identifier>ISSN: 0143-3636</identifier><identifier>EISSN: 1473-5628</identifier><identifier>DOI: 10.1097/00006231-199303000-00003</identifier><identifier>PMID: 8455905</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott-Raven Publishers</publisher><subject>Adult ; Biological and medical sciences ; Endocrine glands ; Female ; Humans ; Iodine Radioisotopes - adverse effects ; Iodine Radioisotopes - therapeutic use ; Male ; Medical sciences ; Public Health ; Radiation Dosage ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Thyrotoxicosis - radiotherapy</subject><ispartof>Nuclear medicine communications, 1993-03, Vol.14 (3), p.160-168</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2313-c2e3615504a953e652560604daa0eab2b8e0ab2aa09afd4bcb06766d6f884ef63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4664274$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8455905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OʼDOHERTY, M J</creatorcontrib><creatorcontrib>KETTLE, A G</creatorcontrib><creatorcontrib>EUSTANCE, C N.P</creatorcontrib><creatorcontrib>MOUNTFORD, P J</creatorcontrib><creatorcontrib>COAKLEY, A J</creatorcontrib><title>Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis</title><title>Nuclear medicine communications</title><addtitle>Nucl Med Commun</addtitle><description>Recommendations for restricting the exposure to radiation of members of the public coming into contact with thyrotoxic patients treated with I are currently based on the activity retained by the patient, and not on the doses likely to be received by such individuals. In order to examine whether these current recommendations restrict these doses to less than the current annual limit of 5 mSv, and to identify the implications of a reduction in this limit to 1 mSv, measurements were made of the dose rates at distances of 0.1, 0.5 and 1.0 m from 60 patients just before they left the nuclear medicine department. These measurements were repeated 1, 3, 6, 8 and 10 days after administration for 30 patients, and the radioactivity in samples of saliva taken on each of these days and secreted in sweat over the first 24 h were also measured. Doses were estimated for administered activities of approximately 200–600 MBq, assuming appropriate values for the times and distances spent near other individuals while travelling, at work, at home and near to young children considered in three age groups (&lt;2, 2–5 and 5–11 years). Periods of restriction were derived which would reduce these doses to 5 or 1 mSv. For a dose limit of 5 mSv, there is no need to restrict private travel, public transport journeys can last up to 7 h, a patient can return to work immediately, but sleeping with a partner will have to be restricted even for the minimum activity of 200 MBq. For a dose limit of 1 mSv, public transport journeys should not exceed 1 h for an administered activity of 600 MBq or 3.5 h for 200 MBq, and return to work should be delayed if the administered activity exceeds 300 MBq. The periods to restrict close contact with young children in order to limit their dose to 1 mSv were very similar to the current recommendations based on retained activity.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Endocrine glands</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes - adverse effects</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Public Health</subject><subject>Radiation Dosage</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Thyrotoxicosis - radiotherapy</subject><issn>0143-3636</issn><issn>1473-5628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UctOwzAQtBColMInIPnANWBnbSc5oopHpUpIFZwjJ1lTQxpHdkrp3-PS0hs-eHd2ZlbWmBDK2S1nRXbH4lEp8IQXBTCIKNmN4ISMucggkSrNT8mYcQEJKFDn5CKEj6jIQWUjMsqFlAWTY7JY6MbqwbqONi4g9XrAQI13K6qbdTvQPpLYDYF6rNF-2e6dcuAzOizR635LjfOx33o3uG9bu2DDJTkzug14dagT8vb48Dp9TuYvT7Pp_Typ48Mh3giKS8mELiSgkqlUTDHRaM1QV2mVI4slokKbRlR1xVSmVKNMngs0CiYk3--tvQvBoyl7b1fab0vOyl1K5V9K5TGl3xFE6_Xe2q-rFTZH4yGWyN8ceB1q3Rqvu9qGo0woJdJMRJnYyzauHdCHz3a9QV8uUbfDsvzvj-AHmAd_Dw</recordid><startdate>199303</startdate><enddate>199303</enddate><creator>OʼDOHERTY, M J</creator><creator>KETTLE, A G</creator><creator>EUSTANCE, C N.P</creator><creator>MOUNTFORD, P J</creator><creator>COAKLEY, A J</creator><general>Lippincott-Raven Publishers</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199303</creationdate><title>Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis</title><author>OʼDOHERTY, M J ; KETTLE, A G ; EUSTANCE, C N.P ; MOUNTFORD, P J ; COAKLEY, A J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2313-c2e3615504a953e652560604daa0eab2b8e0ab2aa09afd4bcb06766d6f884ef63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Endocrine glands</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes - adverse effects</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Public Health</topic><topic>Radiation Dosage</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Thyrotoxicosis - radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OʼDOHERTY, M J</creatorcontrib><creatorcontrib>KETTLE, A G</creatorcontrib><creatorcontrib>EUSTANCE, C N.P</creatorcontrib><creatorcontrib>MOUNTFORD, P J</creatorcontrib><creatorcontrib>COAKLEY, A J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Nuclear medicine communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OʼDOHERTY, M J</au><au>KETTLE, A G</au><au>EUSTANCE, C N.P</au><au>MOUNTFORD, P J</au><au>COAKLEY, A J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis</atitle><jtitle>Nuclear medicine communications</jtitle><addtitle>Nucl Med Commun</addtitle><date>1993-03</date><risdate>1993</risdate><volume>14</volume><issue>3</issue><spage>160</spage><epage>168</epage><pages>160-168</pages><issn>0143-3636</issn><eissn>1473-5628</eissn><abstract>Recommendations for restricting the exposure to radiation of members of the public coming into contact with thyrotoxic patients treated with I are currently based on the activity retained by the patient, and not on the doses likely to be received by such individuals. In order to examine whether these current recommendations restrict these doses to less than the current annual limit of 5 mSv, and to identify the implications of a reduction in this limit to 1 mSv, measurements were made of the dose rates at distances of 0.1, 0.5 and 1.0 m from 60 patients just before they left the nuclear medicine department. These measurements were repeated 1, 3, 6, 8 and 10 days after administration for 30 patients, and the radioactivity in samples of saliva taken on each of these days and secreted in sweat over the first 24 h were also measured. Doses were estimated for administered activities of approximately 200–600 MBq, assuming appropriate values for the times and distances spent near other individuals while travelling, at work, at home and near to young children considered in three age groups (&lt;2, 2–5 and 5–11 years). Periods of restriction were derived which would reduce these doses to 5 or 1 mSv. For a dose limit of 5 mSv, there is no need to restrict private travel, public transport journeys can last up to 7 h, a patient can return to work immediately, but sleeping with a partner will have to be restricted even for the minimum activity of 200 MBq. For a dose limit of 1 mSv, public transport journeys should not exceed 1 h for an administered activity of 600 MBq or 3.5 h for 200 MBq, and return to work should be delayed if the administered activity exceeds 300 MBq. The periods to restrict close contact with young children in order to limit their dose to 1 mSv were very similar to the current recommendations based on retained activity.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>8455905</pmid><doi>10.1097/00006231-199303000-00003</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0143-3636
ispartof Nuclear medicine communications, 1993-03, Vol.14 (3), p.160-168
issn 0143-3636
1473-5628
language eng
recordid cdi_crossref_primary_10_1097_00006231_199303000_00003
source MEDLINE; Journals@Ovid Complete
subjects Adult
Biological and medical sciences
Endocrine glands
Female
Humans
Iodine Radioisotopes - adverse effects
Iodine Radioisotopes - therapeutic use
Male
Medical sciences
Public Health
Radiation Dosage
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Thyrotoxicosis - radiotherapy
title Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A56%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiation%20dose%20rates%20from%20adult%20patients%20receiving%20131I%20therapy%20for%20thyrotoxicosis&rft.jtitle=Nuclear%20medicine%20communications&rft.au=O%CA%BCDOHERTY,%20M%20J&rft.date=1993-03&rft.volume=14&rft.issue=3&rft.spage=160&rft.epage=168&rft.pages=160-168&rft.issn=0143-3636&rft.eissn=1473-5628&rft_id=info:doi/10.1097/00006231-199303000-00003&rft_dat=%3Cpubmed_cross%3E8455905%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8455905&rfr_iscdi=true